FDA Approves First Treg Cell Therapy, Beginning to Rewrite Immune Balance in Blood Cancer Transplantation

Allogeneic hematopoietic stem cell transplantation has long been an important treatment option for multiple hematologic malignancies, but its risks have never been limited to the cancer itself. After transplantation, immune cells from the donor may attack the patient’s tissues and trigger graft-versus-host disease; if it enters the chronic stage, the skin, gastrointestinal tract, liver, and multiple organs may all be affected, leaving patients to bear prolonged and heavy immune complications in addition to tumor control.

The U.S. Food and Drug Administration approved Tregzi on June 30 for adult patients with hematologic malignancies who are receiving matched-donor allogeneic hematopoietic stem cell transplantation and myeloablative conditioning. The FDA said this is the first regulatory T cell-based immunotherapy, with the goal of improving post-transplant “chronic GVHD-free survival”; the approved population includes patients with blood cancers such as acute leukemia and myelodysplastic syndromes.

Tregzi was developed by Orca Biosystems and was previously known clinically as Orca-T. It is not a single drug molecule, but is made from live cells from a matched donor, including purified hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells. The core of this design is to rearrange the immune composition of the graft: providing the cells needed for hematopoietic reconstruction while also attempting to use Tregs to reduce excessive immune attack.

The FDA approval is based primarily on the phase 3 PRECISION-T trial. The study enrolled 187 adult patients with blood cancers. Results showed that the chronic GVHD-free survival rate at one year was 78% among those receiving Tregzi, compared with 38.4% in the standard transplant group. The FDA also noted that the rate of severe chronic GVHD within one year was 12.6% in the Tregzi group and 44% in the standard transplant group. The company separately reported that overall survival was 94% in the Tregzi group and 83% in the standard transplant group, while non-relapse mortality was 3% and 13%, respectively; these figures provide an efficacy profile, but still need to be interpreted within the trial design and the conditions of the study population.

The significance of this therapy lies in shifting the focus of transplant medicine from “whether engraftment can occur” to “how the immune system coexists after engraftment.” Traditional allogeneic transplantation requires repeated trade-offs among antitumor effect, infection risk, and GVHD prevention; if regulatory T cells can reduce immune dysregulation more precisely, patients may not only survive, but also have the opportunity to reduce the burden of long-term immunosuppression and organ damage.

However, the complexity of cell therapy also means it will not be a simple, easily replicated standard drug product. The prescribing information shows that Tregzi is administered as a single dose, but consists of multiple infusion bags containing hematopoietic stem and progenitor cells, Tregs, conventional T cells, and diluent; its dose is calculated according to body weight and the number of viable cells. Label warnings include risks such as graft failure, GVHD, infusion reactions, secondary malignancies, donor-derived malignancies, and transmission of infectious agents.

Common adverse reactions also underscore that this therapy remains within the context of high-intensity transplant care, rather than being a low-burden treatment. Common reactions listed on the label include mucositis, diarrhea, rash, viral infection, abdominal pain, vomiting, nausea, bacterial infection, bleeding, acute GVHD, edema, and fungal infection. In other words, Tregzi’s approval represents a regulatory milestone for transplant immune engineering, but how it will truly change clinical workflows will still depend on center experience, manufacturing and distribution capacity, patient selection, and whether long-term follow-up data can support the early results.